Research & Reviews in Biotechnology & Biosciences **ISSN No: 2321-8681**
Website: www.biotechjournal.in **Review article**
Volume: 11, Issue: 1, Year: 2024 **PP: 35-38**
Peer Reviewed Refereed Journal

UNVEILING THE ENIGMA: ASYMMETRIC SYNTHESIS IN PHARMACEUTICAL EVOLUTION

Ahire Deep Bajirao

MES-Abasaheb Garware College Pune, Maharashtra

Article History

Received: 10/02/2024
Accepted: 28/02/2024

Article ID: RRBB/204

Corresponding Author:
E-Mail:
ahiredeep2001@gmail.com

ABSTRACT

The article discusses the challenges faced by the pharmaceutical industry in the context of declining numbers of new chemical entities (NCEs) introduced to the market. It highlights a shift in research focus towards unexplored biological areas, resulting in a slow translation of technological advancements into fruitful outcomes. Despite significant growth in asymmetric synthesis, a substantial portion of drugs launched in the past decade still lack stereochemical elements. The paper emphasizes the paradigm shift triggered by the FDA's 1992 policy statement, steering drug development away from racemates to single-enantiomer drugs. The potential of asymmetric hydroformylation as a synthetic tool for chiral product preparation is explored, with a focus on its application in various pharmaceutical classes[1]. The need for enantiomerically pure compounds remains a challenge, and the article reflects on the current state and future possibilities of asymmetric synthesis.

Keywords: Pharmaceutical Industry Trends; New Chemical Entities (Nces); Asymmetric; Hydroformylation; Chiral Products.

INTRODUCTION

Chiral auxiliary-based reactions play a vital role in asymmetric synthesis, offering a well-understood approach with broad substrate scope. This abstract highlights the advantages of diastereoselective methods over catalytic processes, emphasizing their robustness and applicability in API synthesis. The use of chiral auxiliaries, including "privileged" controllers like Evans's oxazolidinones, has significantly impacted the synthesis of pharmaceutical ingredients and complex natural products.

Despite their advantages, the auxiliary-based approach has drawbacks, such as additional steps for removing and attaching the chiral auxiliary. Addressing the separation of the auxiliary from the product, especially on a process scale, is a challenge[2]. Strategies involving differences in physical properties, such as pKa or solubility, are discussed for efficient separation and recovery of the chiral auxiliary, promoting cost-effectiveness and environmentally friendly processes.

This delves into specific examples, focusing on aldol reactions with chiral enolates, with a detailed exploration of propionate-type and acetate-type aldol reactions. It highlights the successful application of these methods in the synthesis of pharmaceuticals, such as ((-threo-Methylphenidate hydrochloride) (ritalin hydrochloride), PNP405, and antihyperglycemic agents[1].

Additionally, the abstract touches upon chiral auxiliary-controlled alkylation reactions, exemplifying their significance in large-scale

API synthesis. Examples include the synthesis of compounds like PNP405 and Pfizer's Rvâ3 integrin antagonist.

Finally, the it touches on enantioselective processes facilitated by stoichiometric chiralligands, providing examples of processes that utilize chiral ligands like B-chlorodiisopinocampheylborane for asymmetric reduction of ketones[2]. Several case studies, including syntheses of AL-4862 and trecetilide hemi-fumarate, illustrate the application of stoichiometric chiral ligands in large-scale processes.

MATERIAL AND METHODS

Streamlining Chiral Auxiliary-Based Reactions

Chiral auxiliary-based reactions, known for well-understood reaction mechanisms and broad substrate scopes, offer predictable stereochemical control. Compared to catalytic processes, diastereoselective methods exhibit robustness on a larger scale and are less sensitive to impurities. The purification of desired products is typically more straightforward due to dia-stereoisomericbyproducts. This results in a shorter development time, proving valuable for rapid API delivery in preclinical and early clinical studies. Numerous chiral auxiliaries, including "privileged" controllers like Evans's oxazolidinones, have significantly impacted asymmetric synthesis[1].

Chiral auxiliary-controlled aldol reactions play a crucial role in the synthesis of Active Pharmaceutical Ingredients (APIs). These reactions enable the formation of one C-C bond have two stereogeniccenters in a only step, offering efficiency in the synthesis process[1].

Chiral Auxiliaries inAldol reactions

It plays a crucial role in the synthesis of APIs(Active Pharmaceutical Ingredients) . These reactions enable the formation of one C-C bond having two stereogeniccenters in a singlestep, offering efficiency in the synthesis process.aldol reactions are includes two types an enolates derived from any acetate have R-substituent (propionate-type) and those without R substituents (acetate-type)[6].

In propionate-type aldol reactions, various chiral auxiliaries, such as Evans's oxazolidinones, have demonstrated reliability and practicality, ensuring high diastereoselectivity. An exemplary application includes synthesis of discodermolide, a natural product use for cancer treatment, showcasing the efficiency of Evans aldol reactions on multi-kilogram scales.

However, acetate-type aldol reactions have posed challenges in achieving stereocontrol. Braun's reagent, 2-acetoxy-1,1,2-triphenylethanol, has been employed for limited success in selective acetate aldol reactions. Applications include the synthesis of fluvastatin, an antihyperlipoproteinemic agent.

2 Chiral Auxiliary-Controlled Alkylation

Alkylation of metal enolates derived from derivatives of carboxylic acid which is a crucial C-C bond-forming reaction, often controlled by chiral auxiliaries like Evans's oxazolidinones[4] or Myers's pseudoephedrine amides[4]. These asymmetric alkylation methods, owing to their reliability, cost-effectiveness, and large-scale applicability, are widely employed in API synthesis. The compounds, such as endothelin receptor antagonist ABT-627 and Hoffmann-La Roche's MMP inhibitor trocade, showcase successful applications of chiral auxiliary-based alkylation reactions in the synthesis of pharmaceuticals on metric ton scales. Additionally, Myers's pseudoephedrine proves practical in synthesis of CGP60536B, an active inhibitor. These examples highlight the efficiency and versatility of chiral auxiliary-controlled alkylation reactions in the pharmaceutical industry, enabling the synthesis of complex molecules with high stereoselectivity on a large scale.an extremely deleterious effect on the enantioselectivity.

Research & Reviews in Biotechnology & Biosciences **ISSN No: 2321-8681**
Website: www.biotechjournal.in **Review article**
Volume: 11, Issue: 1, Year: 2024 **PP: 35-38**
Peer Reviewed Refereed Journal

DISCUSSION

1.Challenges and Trends in Chiral Synthesis: A Critical Analysis of Pharmaceutical Approaches

In the analysis of methods for synthesizing chiral compounds, particularly focusing on single-enantiomer drugs in the market, the review examines various processes. The gathered data, while incomplete, suggests that a significant portion of chirality in drugs comes from the chiral pool, existing in nature. Despite alternative viable approaches, asymmetric synthesis is infrequently employed. Challenges in adopting modern asymmetric synthesis, tight timelines, and the reluctance to deviate from established routes are discussed. The use of classical resolution methods remains prevalent due to simplicity and efficacy. Patenting of chiral ligands and catalysts often hinders industrial adoption, with pharmaceutical companies favoring patent-free alternatives[2]. The practical potential of asymmetric technologies is assessed based on key chiral intermediates' price and availability[1]. The review, drawn from recent literature, highlights the limited implementation of asymmetric approaches in the pharmaceutical industry and aims to raise awareness of underexplored methods. The analysis focuses on truly asymmetric technologies, excluding diastereoselective transformations and resolution processes. The efficiency, scale, and practicality of each method are evaluated, offering insights into practiced technologies within the pharmaceutical industry.

2.Navigating Challenges in Asymmetric Catalysis for Pharmaceutical Synthesis: Progress,Limitations, and Practical Considerations

The principles and challenges of asymmetric catalysis in pharmaceutical synthesis. It outlines the process where a prochiral substrate and a nonchiral reagent are in contact in the presence of a catalyst which is chiral that gives desired enantiomer. The key challenge is ensuring the catalyst/reagent complex's higher reactivity compared to the substrate, maintaining efficient cycling, and achieving exquisite selectivity for one enantiomer. Despite the complexity, significant progress in enantioselective catalysis has been made in the last decade. However, these catalysts face challenges in competing with established processes, especially in terms of optimization, catalyst procurement on a large scale, and concerns about cost and catalyst removal from the final product. The article emphasizes the limited acceptance of catalytic tools in API synthesis, highlighting the prevalence of reductive and oxidative processes over C-C bond-forming reactions, which, while synthetically elegant, are less utilized in industry. The text suggests that although some examples presented may be synthetically elegant curiosities, they could inspire process chemists to explore new methodologies for practicality, robustness, and cost-effectiveness in pharmaceutical synthesis[2].

CONCLUSION

Over the past decade, asymmetric catalysis has experienced substantial growth, gaining prominence in the pharmaceutical industry for synthesizing single enantiomer APIs on a larger scale[4]. Industrial process chemists acknowledge the significance of incorporating these catalytic techniques into API syntheses, aiming to create cost-efficient, scalable, and eco-friendly processes, as emphasized in this review. While practical challenges related to asymmetric catalysis, such as intellectual property issues, economic considerations, and limited commercial affinity of ligamd and catalyst.still need addressing, the intrinsic efficiency of asymmetric catalysis suggests a promising future for its widespread adoption in API synthesis within the pharmaceutical industry[4].

ACKNOWLEDGEMENT

Author acknowledge to Dr. Vilas Ugale, Principal of MES abasahebGarware college and Dr.ShobhaWaghmode, HOD of chemistry dept.

MES abasahebGarware college pune, Maharashtra

REFERENCES

1. AzadehNazari, Majid M. Heravi, VahidehZadsirjan. "Oxazolidinones as chiral auxiliariesin asymmetric aldol reaction applied tonatural products total synthesis", Journal ofOrganometallic Chemistry, 2020
2. Vittorio Farina, Jonathan T. Reeves, Chris H.Senanayake, Jinhua J. Song. "Asymmetric Synthesis of Active Pharmaceutical Ingredients", Chemical Reviews, 2006
3. Seyden-Penne, J. Chiral Auxiliaries and Ligands in AsymmetricSynthesis; John Wiley: New York, 1995
4. Asymmetric Synthesis of Active Pharmaceutical IngredientsVittorio Farina,Jonathan T. Reeves, Chris H. Senanayake, and Jinhua J. SongDepartment of Chemical Development, BoehringerIngelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877
5. Palomo, C.; Oiarbide,M.; Garcia, J. M. Chem.sEur. J. 2002, 8, 37.
6. Nathan M. Lui, Samantha N. MacMillan, David B. Collum. LithiatedOppolzerEnolates: Solution Structures, Mechanism of Alkylation, and Origin of Stereoselectivity. Journal of the American Chemical Society 2022, 144 (51) , 23379-23395.
7. Preeti Nigam, Shobha Waghmode, Michelle Louis, Shishanka Wangnoo, Pooja
8. Chavan and Dhiman Sarkar. Graphene quantum dots conjugated albumin nanoparticlesfor targeted drug delivery and imaging of pancreatic cancer. J. Mater. Chem. B, 2014, 2, 3190-3195, DOI: 10.1039/C4TB00015C.
9. Omkar Pawar, Neelima Deshpande, Sharada Dagade, Preeti Nigam-Joshie, Shobha Waghmode. Green synthesis of silver nanoparticles from purple acid phosphatase apo-enzyme Omkar isolated from a new source Limonia acidissima. J.of Expt.Nanoscience.,doi.org/10.1080/17458080.2015.1025300, Published online: 27 Mar 2015.
10. Graphene Foam: Next Generation Graphene Analogue, Butala Deepali and Waghmode Shobha, Research Journal of Chemistry and Environment Vol. 24 (8)August (2020), 1-11.
11. Patil, U.D., Waghmode, S., Pingale, S.S. et al. Quinoline-infused graphene carbon cages: an ecofriendly approach towards environmental remediation. Res Chem Intermed 49, 4217–4237 (2023). https://doi.org/10.1007/s11164-023-05098-0.
12. Shobha Waghmode, Pooja Chavan,Vidya Kalyankar,and Sharada Dagade.Synthesis of Silver Nanoparticles Using Triticum aestivum and Its Effect on Peroxide Catalytic Activity and Toxicology. Journal of Chemistry, Volume 2013, Article ID 265864, 5 pages, http://dx.doi.org/10.1155/2013/265864.